Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $23.8 million.

  • Spyre Therapeutics' Accumulated Expenses rose 8115.26% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 8115.26%. This contributed to the annual value of $27.7 million for FY2024, which is 11140.52% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Accumulated Expenses stood at $23.8 million, which was up 8115.26% from $19.4 million recorded in Q2 2025.
  • Spyre Therapeutics' Accumulated Expenses' 5-year high stood at $28.4 million during Q2 2023, with a 5-year trough of $5.7 million in Q2 2024.
  • For the 5-year period, Spyre Therapeutics' Accumulated Expenses averaged around $15.8 million, with its median value being $13.2 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' Accumulated Expenses crashed by 8000.84% in 2024, and later soared by 24165.05% in 2025.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Accumulated Expenses stood at $14.0 million in 2021, then decreased by 8.5% to $12.8 million in 2022, then grew by 2.11% to $13.1 million in 2023, then soared by 111.41% to $27.7 million in 2024, then dropped by 14.02% to $23.8 million in 2025.
  • Its Accumulated Expenses stands at $23.8 million for Q3 2025, versus $19.4 million for Q2 2025 and $21.6 million for Q1 2025.